Esri Signs Training Protocol Agreement with Chamber of Geophysical Engineers of Turkey
Esri, the global leader in location intelligence, today announced an agreement with the Chamber of Geophysical Engineers of Turkey (CGET), whereby the chamber's members will be entitled to special discounts on training for Esri's ArcGIS software. Now, all geophysical engineers registered in the organization will be able to take ArcGIS training courses, allowing them to qualify as GIS experts to better fulfill the demands of the growing employment market.
CGET is a nonprofit organization that promotes the expert and ethical practice of geophysics in the exploration and development of natural resources, in characterizing the near surface, and in mitigating earth hazards. Members are involved in groundwater exploration, mineral and petroleum exploration, archaeological research, seismology, and other scientific activities.
CGET has more than 5,000 active members, so it is important to find ways to scale access to the most innovative geospatial technologies for these kinds of professional associations. Şevket Demirbaş, president of the Association of Geophysical Engineers, emphasized that today, every geophysical engineer should be proficient in GIS due to the increasing importance of spatial analysis in the field. In 2020, the portion of sales in geospatial technology training derived from professional associations in Turkey amounted to 37 percent.
This training protocol agreement Esri has signed with CGET marks the first step toward cooperation between these two institutions. The collaboration will enable chamber members to use the knowledge they have learned through ArcGIS training to contribute to Turkey's commercial, public service, and scientific research sectors.
To learn more about Esri's training agreements with other chambers in Turkey, visit esri.com.tr/tr-tr/hakkinda/haberler/genel-bakis.
Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping, helps customers unlock the full potential of data to improve operational and business results. Founded in 1969 in Redlands, California, USA, Esri software is deployed in more than 350,000 organizations globally and in over 200,000 institutions in the Americas, Asia and the Pacific, Europe, Africa, and the Middle East, including Fortune 500 companies, government agencies, nonprofits, and universities. Esri has regional offices, international distributors, and partners providing local support in over 100 countries on six continents. With its pioneering commitment to geospatial information technology, Esri engineers the most innovative solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com.
Copyright © 2021 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Jo Ann Pruchniewski
Public Relations, Esri
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 202123.6.2021 13:00:00 CEST | Press release
Brii Biosciences (“Brii Bio”) and VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), today announced final results from a Phase 1b/2a study on BRII-179 (VBI-2601), a novel recombinant, protein-based immunotherapeutic candidate, in patients with chronic hepatitis B virus (HBV) infection. Data from the study, which evaluated the safety, antiviral activity, and immunogenicity of BRII-179 (VBI-2601) alone or admixed with interferon-alpha (IFN-α) as co-adjuvant, demonstrated that the investigational immunotherapeutic induced both B cell (antibody) and T cell responses, and was well-tolerated with no safety signals observed, in non-cirrhotic chronic hepatitis B patients under nucleos(t)ide analog (NUC) therapy. The study was led by Brii Bio in partnership with VBI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210623005322/en/ The data, as presented in a late-breaker e-Poster at the European Association for the Study of the Liver’s (EASL)
Amazon Becomes Largest Corporate Buyer of Renewable Energy in the U.S.23.6.2021 12:00:00 CEST | Press release
Amazon (NASDAQ: AMZN) today announced 14 new renewable energy projects in the U.S., Canada, Finland, and Spain to advance its ambitious goal to power 100% of company activities with renewable energy by 2025—five years ahead of the original target of 2030. The new projects bring Amazon’s total renewable energy investments to date to 10 gigawatts (GW) of electricity production capacity—enough to power 2.5million U.S. homes. Amazon is now the largest corporate buyer of renewable energy in the U.S. and the world. The latest utility-scale solar and wind projects will supply renewable energy for Amazon’s corporate offices, fulfillment centers, and Amazon Web Services (AWS) data centers that support millions of customers globally. These projects will also help Amazon meet its commitment to produce enough renewable energy to cover the electricity used by all Echo devices in use. These new projects support hundreds of jobs while providing hundreds of millions of dollars of investment in local c
Quanta Raises $245 Million to Accelerate Commercialization of its SC+ Portable Hemodialysis System23.6.2021 12:00:00 CEST | Press release
Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical technology leader delivering on its vision for more flexible and accessible dialysis care, announced today that it has raised $245 million in an oversubscribed and upsized Series D round, the largest private funding round for a dialysis device company in history. “We are delighted to attract such a strong syndicate of investors, which represents a clear vote of confidence in our innovative approach to dialysis treatment,” said John E. Milad, CEO of Quanta. “Everybody knows that dialysis care must improve. For this to happen, providers and physicians need products that allow greater flexibility to bring dialysis directly to the patient, while simplifying complexity and reducing the overall cost of care. Our small, simple-to-use, and powerful dialysis system SC+ is positioned to help transform kidney care. The funding we are announcing today will allow us to accelerate our emergence as a significant force in this mar
AntChain Launches Developer Support Program to Foster Global Collaboration on Blockchain and Other Innovations23.6.2021 10:50:00 CEST | Press release
AntChain, Ant Group’s technology brand, today launched a developer community support program at its first developer conference. The program is designed to further foster trusted industry collaboration networks with blockchain, secure computing, IoT, and other innovative technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210623005429/en/ Geoff Jiang, President of Ant Group’s Intelligent Technology Business Group (Photo: Business Wire) This new program will bring AntChain's technical know-how and industry experience to partners and developers across a variety of platforms. Among them, the AntChain open technology platform will serve to accelerate the development of blockchain applications as well as reduce costs, while the AntChain open business ecosystem will help connect partners and developers with complementary business opportunities and operational resources. A new talent certification system has also been put i
Teijin Receives Additional Approval in Japan for Merz’s Xeomin ® Botulinum Toxin Type A23.6.2021 10:00:00 CEST | Press release
Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, and Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, jointly announced today that Teijin Pharma has been granted additional approval by Japan’s Ministry of Health, Labor and Welfare (MHLW) to market Xeomin® (incobotulinumtoxinA) for intramuscular injection in 50, 100 or 200 units for the treatment of lower limb spasticity. Lower limb spasticity is a symptom of upper motor neuron syndrome, which is expressed mainly by increased muscle tone of limbs and the hyperexcitability of the stretch reflex as a sequela of stroke. The main symptoms are difficulty in normal walking and increased risk of falling due to trunk instability, complicating or impeding activities in daily life. Conventional treatment of lower limb spasticity includes physical rehabilitation and the use of oral muscle relaxants or neuromuscular blockers such as botulinum toxin type A. Stefan Brinkmann,
B2B Payment Provider, ZTL, Selects Napier’s Anti-financial Crime Solutions23.6.2021 10:00:00 CEST | Press release
RegTech company, Napier, provider of advanced anti-financial crime compliance solutions, has announced its AI-led technology has been chosen by emerging Norwegian FinTech, ZTL Payment Solution. Napier will supply the B2B payment provider with Transaction Screening, Transaction Monitoring and Client Screening. These tools will enhance ZTL’s ability to identify suspicious activity related to money laundering through transaction monitoring, while also identifying potential risk of breaching sanctions with screening solutions. Founded in 2018, ZTL’s platform integrates with accounting system providers via API building blocks, providing a customized solution to facilitate for payments directly from the accounting system. ZTL will use Napier’s screening and monitoring solutions to meet regulatory compliance obligations, spot suspicious activities, and mitigate money laundering and sanctions risks. Andreas Bjerke, CEO at ZTL, said: “We are one of the first Norwegian licensed payment providers
ISAE-SUPAERO Announces Its New Specialized Master's Degree23.6.2021 09:30:00 CEST | Press release
The Institut Supérieur de l'Aéronautique et de l'Espace (ISAE-SUPAERO) in Toulouse now offers a professional certification in Artificial Intelligence and Data Science, based on the Specialized Master's Degree® AIBT (Artificial Intelligence & Business Transformation. Offered in partnership with TBS Education and IRT Saint-Exupéry, this part-time training program prepares professionals, apprentices and young graduates for this new profession that is in high demand on the job market. Admissions are open until September 15, 2021. This certification will be offered from the beginning of the new academic year to professionals, apprentices aged 25 to 30 and young graduates (Bac+5) wishing to prepare for the job of "Project Manager in Artificial Intelligence and Data Science (MS)". Certified by the RNCP number 35609, this training is entirely taught in English. This registration in the National Directory by France Compétences allows professionals to mobilize their CPF (Personal Training Accoun
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom